



Temporal Trends of Antithrombotic Therapy in Patients With Acute Myocardial Infarction and Atrial Fibrillation: Insight From the KAMIR-NIH Registry

Oh-Hyun Lee¹, Yongcheol Kim^{1*}, Deok-Kyu Cho¹, Jung-Sun Kim², Byeong-Keuk Kim², Donghoon Choi¹, Myeong-Ki Hong², Myung Ho Jeong³, Yangsoo Jang⁴ and the KAMIR-NIH Investigators

¹ Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yonjin Severance Hospital, Yonjin, South Korea, ² Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea, ³ Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, South Korea, ⁴ Department of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, South Korea

OPEN ACCESS

Edited by:

Giuseppe Ando,
University of Messina, Italy

Reviewed by:

Arturo Cesaro,
University of Campania Luigi
Vanvitelli, Italy
Giovanni Cimmino,
University of Campania Luigi
Vanvitelli, Italy

*Correspondence:

Yongcheol Kim
Yongcheol@yuhs.ac

Specialty section:

This article was submitted to
Cardiovascular Therapeutics,
a section of the journal
Frontiers in Cardiovascular Medicine

Received: 20 August 2021

Accepted: 05 October 2021

Published: 25 November 2021

Citation:

Lee O-H, Kim Y, Cho D-K, Kim J-S,
Kim B-K, Choi D, Hong M-K,
Jeong MH, Jang Y and the
KAMIR-NIH Investigators (2021)
Temporal Trends of Antithrombotic
Therapy in Patients With Acute
Myocardial Infarction and Atrial
Fibrillation: Insight From the
KAMIR-NIH Registry.
Front. Cardiovasc. Med. 8:762090.
doi: 10.3389/fcvm.2021.762090

Background: Triple therapy is the combination of dual antiplatelet therapy plus oral anticoagulant after stent implantation. Current guidelines recommend triple therapy for acute coronary syndrome with atrial fibrillation (AF). This study aimed to identify temporal trends of antithrombotic therapy in patients with acute myocardial infarction (AMI) and AF.

Methods: Among 13,104 consecutive patients from the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) registry, we identified 453 patients with AF after stent implantation for AMI; these patients were then divided into those who did and did not use oral anticoagulant (OAC) [OAC group ($n = 71$) vs. non-OAC group ($n = 382$), respectively].

Results: The results showed that the prevalence of AF in AMI patients was 5.4% (712/13,104). Among 453 patients, only 15.7% (71/453) were treated with OAC while dual or single antiplatelet therapy was provided for 84.7% (382/453) of patients. In patients with high stroke risk (CHA₂DS₂-VASc score ≥ 2), OACs were used only in 17% (69/406). Multivariate analysis revealed that female sex [odds ratio (OR) 2.11; 95% CI: 1.17–3.79], diabetes mellitus (DM) (OR 2.37; 95% CI: 1.35–4.17), prior cerebrovascular accident (CVA) (OR 4.19; 95% CI: 2–8.75), and congestive heart failure (CHF) (OR 1.89; 95% CI: 1.09–3.3) as the significant determinants of OAC use.

Conclusion: The study concluded that OAC was underused. Approximately, 15%, of AMI patients with AF undergoing PCI with stent and female gender, DM, prior CVA history, and a history of CHF or the presence of moderate to severe left ventricle systolic impairment were significant determinants of OAC use.

Keywords: atrial fibrillation, myocardial infarction, percutaneous coronary intervention, anticoagulants, treatment outcome

INTRODUCTION

Atrial fibrillation is the most common arrhythmia and is associated with increased morbidity and mortality, including thromboembolic events (1). The prevalence of atrial fibrillation (AF) is increasing globally and has been projected to increase to 5.6 million individuals in the USA by the year 2050 and 8.8 million adults over 55 years in Europe by the year 2060, indicating substantial public health and economic burden (2). AF is associated with an increased risk of acute myocardial infarction (AMI) and the presence of AF during AMI has been associated with a worse prognosis (3, 4).

In AF patients, oral anticoagulant (OAC) is required to reduce the risk of thromboembolic events, whereas antiplatelet therapy is essential to prevent thrombotic events, including stent thrombosis, in patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). However, there are concerns regarding the major bleeding due to the intensive combination antithrombotic therapy (5, 6). Thus, current guidelines recommend that early cessation of aspirin and continuation of dual antithrombotic therapy with an OAC plus clopidogrel up to 6–12 months in patients with AF at increased risk of stroke (CHA₂DS₂-VASc score \geq 2) who have undergone PCI with stent implantation for ischemic heart disease (7, 8).

However, despite the recommendations of the current guidelines, a previous nationwide population-based study reported that only 22.7% of patients received triple therapy, i.e., the combination of dual antiplatelet therapy (DAPT) plus OAC, after PCI although 96.2% of them were indicated for anticoagulation (9). Until now, there is a paucity of data regarding the status of anticoagulant usage in AF patients who underwent PCI with stent implantation for AMI. Therefore, this

study aimed to identify the trends in OAC usage patterns and the variables associated with the use of OAC from the real world in patients with AF presenting AMI who underwent PCI with stent implantation.


MATERIALS AND METHODS

Study Design and Subjects

The study population in the current study was selected from the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) registry, a nationwide prospective multicenter registry of patients with AMI in the Republic of Korea without any exclusion criteria. Furthermore, 20 tertiary university hospitals with facilities for primary PCI and onsite cardiac surgery participated in this registry. The detailed study protocol has been previously published (10). After discharge, clinical follow-up was carried out by patient visits or telephone interviews at 6 and 12 months. All data were assessed by independent clinical research coordinators using a web-based case report form on the internet-based Clinic Research and Trial management system. Clinical outcomes were monitored and centrally adjudicated by an independent event adjudication committee.

Among the consecutive patients with AMI enrolled from November 2011 to December 2015, we excluded the patients who died during the hospitalization for AMI and patients who were lost to follow-up during the 1-year follow-up period.

This study complied with the provisions of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of each participating center. The approval number was CNUH-2011-172 at Chonnam National University Hospital. All patients provided written informed consent.



Definitions

Congestive heart failure (CHF)/left ventricular dysfunction, hypertension, age ≥ 75 years (doubled), diabetes, stroke (doubled)-vascular disease, 65–74 years of age, and sex category (female) [CHA₂DS₂-VASc]. Score was calculated for all patients (8, 11). In this score, the C was defined as the history of congestive heart failure (CHF) or the presence of moderate to severe LV systolic impairment [left ventricular ejection fraction (LVEF) $\leq 40\%$] on transthoracic echocardiography. According to a major criterion of the Academic Research Consortium for High Bleeding Risk (ARC-HBR), anemia and thrombocytopenia were defined as the hemoglobin level < 11 g/dl and platelet count $< 100 \times 10^9/L$, respectively (12). Severe chronic kidney disease was defined as a severe or end-stage renal disease, with an estimated glomerular filtration rate (eGFR) < 30 ml/min (12).

Statistical Analysis

Normally distributed continuous variables are expressed as $M \pm SD$. All categorical variables were presented as numbers with percentile values. Time-to-event data are presented using Kaplan-Meier estimates. The hazard ratios (HR) with 95% CI were estimated from a Cox proportional hazards model. To identify the determinants for the use of OAC, we performed univariate and multivariate analyses. Any variable with a $p < 0.10$ on univariate analysis was included in the multivariate models. Comparison of clinical outcomes between two groups was assessed after adjustment for multiple risk factors using the logistic regression model with the inverse probability of treatment weighting (IPTW). All statistical analyses were performed with SPSS statistical software (SPSS version 25 for Windows; IBM Corp., Armonk, NY, USA).

RESULTS

Among the entire 13,104 patients from the KAMIR-NIH registry, the prevalence of AF was 5.4% (712/13, 104) and the trend of annual AF incidence in patients with AMI was stable (p -value for trend = 0.21) (Figure 1). Of these patients, 17% (121/712) patients have been newly diagnosed AF after AMI. A total of 453 eligible patients with AF and AMI treated with stent implantation were analyzed. The mean age was 68.5 ± 12 years (range: 37–92 years), and 337 (74.4%) of the patients were men. The mean CHA₂DS₂-VASc Score was 3.7 ± 1.7 .

Among 453 patients who underwent PCI with stent implantation successfully and were discharged, only 15.7% of patients were treated with OAC although 89.6% of them were indicated for anticoagulation (CHA₂DS₂-VASc score ≥ 2). The study population was classified into two groups according to the OAC usage after stent implantation as follows: patients who used OAC according to the clinical guidelines ($n = 71$, 15.7%) and did not use OAC ($n = 382$, 84.3%) (Supplementary Figure 1). Baseline characteristics of the study population are presented in Table 1. Compared with patients treated without OAC, those using OAC were higher rates of female, diabetes mellitus, current smoker, a history of cerebrovascular accident, and moderate to severe left ventricular systolic dysfunction. Aspirin and clopidogrel were used more frequently in OAC groups, while

TABLE 1 | Baseline characteristics.

Characteristics	OAC ($n = 71$)	No OAC ($n = 382$)	p -value
Age, years	70.6 \pm 10.5	68.1 \pm 12.3	0.08
Female gender	27 (38.0)	89 (23.3)	0.01
Height, cm	163.2 \pm 9.1	165.2 \pm 8.6	0.08
Weight, kg	65.2 \pm 10.9	65.3 \pm 11.78	0.95
Body mass index, kg/m ²	24.3 \pm 2.0	23.8 \pm 3.5	0.24
Hypertension	49 (69.0)	217 (56.8)	0.06
Diabetes mellitus	33 (46.5)	88 (23.0)	<0.01
Dyslipidemia	9(12.7)	26 (6.8)	0.09
Current smoking	11 (15.5)	133 (34.8)	<0.01
Prior myocardial infarction	6 (8.5)	27 (7.1)	0.68
Prior cerebrovascular accident	17 (23.9)	23 (6.0)	<0.01
Prior congestive heart failure	5 (7.0)	12 (3.1)	0.16
Clinical presentation			
NSTEMI	38 (53.5)	163 (42.7)	0.09
STEMI	33 (46.5)	219 (57.3)	
Killip class 3/4	17 (23.9)	86 (22.5)	0.79
LVEF, %	47.3 \pm 11.7	51.0 \pm 10.7	0.01
LVEF $\leq 40\%$	22 (31.0)	53 (13.9)	<0.01
Vital sign			
Systolic BP, mmHg	122.5 \pm 29.6	119.3 \pm 34.1	0.46
Diastolic BP, mmHg	76.1 \pm 20.1	72.8 \pm 21.2	0.23
Heart rate, beats per min	88.6 \pm 20.6	81.3 \pm 27.2	0.01
Laboratory findings			
Peak troponin I, pg/ml	47.0 \pm 76.4	51.0 \pm 84.6	0.73
Total cholesterol, mg/dL	151.5 \pm 48.5	168.2 \pm 39.0	0.01
Triglyceride, mg/dL	104.0 \pm 64.8	117.2 \pm 81.5	0.22
HDL-cholesterol, mg/dL	41.4 \pm 13.7	42.9 \pm 12.0	0.39
LDL-cholesterol, mg/dL	95.1 \pm 38.3	103.7 \pm 35.5	0.08
Creatinine, mg/dL	1.2 \pm 1.5	1.2 \pm 0.9	0.91
Hemoglobin, g/dL	13.5 \pm 2.1	13.8 \pm 2.1	0.35
Platelet count, $10^3/\mu L$	219.3 \pm 63.6	213.7 \pm 60.0	0.47
CRP, mg/L	1.7 \pm 4.3	1.9 \pm 7.6	0.85
NT-proBNP, pg/mL	4195.7 \pm 5662.6	4007.1 \pm 12351.7	0.91
Discharge medication			
Aspirin	68 (95.8)	381 (99.7)	0.01
P2Y ₁₂ inhibitor	70 (98.6)	378 (99.0)	0.58
Clopidogrel	64 (90.1)	288 (75.4)	<0.01
Prasugrel	3 (4.2)	30 (7.9)	0.45
Ticagrelor	3 (4.2)	60 (15.7)	<0.01
ACEi or ARB	59 (83.1)	299 (78.3)	0.36
Beta-blocker	55 (77.5)	315 (82.5)	0.32
Calcium channel blocker	5(14.7)	29 (7.6)	1.00
Statin	63 (88.7)	360 (94.2)	0.09

Data are presented as the Mean \pm SD or number (%).

OAC, oral anticoagulant; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein; NT-proBNP, N-terminal pro-B-type Natriuretic peptide; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

ticagrelor was used more often in the non-OAC group than in the OAC group. Other baseline characteristics were comparable between the two groups.

TABLE 2 | Detailed information on antithrombotic therapy.

Characteristics	OAC (n = 71)	No OAC (n = 382)
Triple therapy	67 (94.4)	Dual antiplatelet therapy 378 (99.0)
OAC + Aspirin + Clopidogrel	61 (85.9)	Aspirin + Clopidogrel 288 (75.4)
OAC + Aspirin + Prasugrel	3 (4.2)	Aspirin + Prasugrel 30 (7.9)
OAC + Aspirin + Ticagrelor	3 (4.2)	Aspirin + Ticagrelor 60 (15.7)
OAC + single antiplatelet therapy	4 (5.6)	Single antiplatelet therapy 4 (1.0)
OAC + Aspirin	1 (1.4)	Aspirin 4 (1.0)
OAC + Clopidogrel	3 (4.2)	Clopidogrel 0
OAC monotherapy	0	No antithrombotic therapy 0

Data are presented as the number (%). OAC, oral anticoagulant.

TABLE 3 | Changes of antithrombotic trends between discharge and 12-month follow-up visit.

Medication at discharge	N = 453	Medication at 12-month	N = 453
Triple therapy	67 (14.8)	Triple therapy	46 (10.2)
Dual therapy	4 (0.9)	Dual therapy	11 (2.4)
OAC monotherapy	0	OAC monotherapy	14 (3.1)
Dual antiplatelet therapy	378 (83.4)	Dual antiplatelet therapy	288 (63.6)
Single antiplatelet therapy	4 (0.9)	Single antiplatelet therapy	48 (10.6)
No antithrombotic therapy	0	No antithrombotic therapy	5 (1.1)
		No available data	41 (9.1)
Detail changes of antithrombotic trends in patients treated with triple therapy at discharge			
Triple therapy	67 (14.8)	Triple therapy	39 (58.2)
		Dual therapy	6 (9.0)
		OAC monotherapy	0
		Dual antiplatelet therapy	13 (19.4)
		Single antiplatelet therapy	2 (3.0)
		No antithrombotic therapy	0
		No available data	7 (10.4)

Data are presented as the number (%).

Angiographic and procedural characteristics are listed in **Supplementary Table 1**. Among these, disease extent, the total number of implanted stents, mean stent diameter, and total stent length did not significantly differ between the two groups, except for the distribution of infarct-related arteries.

Regarding the trends of antithrombotic therapy in both groups, among the 71 patients in the OAC group, triple therapy was used in 67 (94.4%) patients. The majority of patients with triple therapy received clopidogrel (61/67). Only four patients in the OAC group were treated with dual therapy. In patients treated without OAC, 378 (99%) patients received DAPT and four (1%) patients treated with single antiplatelet treatment (SAPT) (**Table 2**). Detailed information on the antithrombotic treatment at discharge and after 12 months is summarized in **Table 3** and **Figure 2**.

The scores in CHA₂DS₂-VASC of the study population are described in **Table 4**. Mean CHA₂DS₂-VASC score was significantly higher in the OAC group than in the non-OAC group (4.7 ± 1.6 vs. 3.6 ± 1.7, *p* < 0.01), and the proportion of patients with a score of 2 or more were much higher in the OAC


than in the non-OAC group [97.2% (69/71) vs. 88.2% (337/382), *p* = 0.02] (**Supplementary Figure 2**). The detailed distributions of the CHA₂DS₂-VASC scores are shown in **Figure 3**. Among the 453 study patients, 406 had a high risk of stroke (CHA₂DS₂-VASC Score ≥ 2). However, OAC was used only in 17% (69/406). In the low to intermediate stroke risk group (CHA₂DS₂-VASC Score < 2), 4.3% (2/47) of patients were treated with OAC. Among the components of the CHA₂DS₂-VASC score, the OAC group had a higher prevalence of CHF, diabetes mellitus, prior stroke, TIA or thromboembolism history, age 65–74 years, and female gender (**Table 4**).

In the multivariate analyses for the determinants of the use of OAC, female gender, diabetes mellitus, and prior CVA history were significant determining factors. History of CHF or the presence of moderate to severe left ventricle (LV) systolic impairment (LVEF ≤ 40%) was also a significant determinant (**Table 5**).

During a 1-year follow-up, there were 44 major adverse cardiovascular and cerebrovascular events (MACCE) (28 all-cause deaths, five MIs, and six cerebral infarctions or

TIA) after stent implantation, and no significant difference was noted between the OAC and non-OAC groups in both the crude- and IPTW-analyses (Supplementary Table 2).

The rates of MACCE, composite all-cause death and MI, composite cardiac death, and MI were also not significantly different between the two groups in both the crude- and IPTW-analyses.



DISCUSSION

The principal findings of the current study were as follows: (1) in real-world practice, the prevalence of AF in AMI patients was 5.4%; (2) only 15.7% of total AMI patients were treated with OAC although 89.6% of them were indicated for anticoagulation (CHA₂DS₂-VASc score ≥ 2); (3) the significant determinants for the use of OAC were female gender, diabetes mellitus, prior CVA history, and a history of CHF or the presence of moderate to severe LV systolic impairment.

The prevalence of AF in the entire Korean population was reported to be 67% in a previous study using the National Health Insurance Service database from 2008 to 2015 and the incidence and prevalence of AF increased in the Korean population over time (13). However, the prevalence of AF in Korean AMI patients has not been reported to date. Previous studies with the western population reported that AF occurred in 7.2–13.2% of patients with AMI (14, 15). In the China registry, the prevalence of AF was reported to be 3% in AMI patients (16). In the current nationwide study, the prevalence of AF in AMI patients was 5.4% and the trend of annual AF incidence in patients with AMI was stable. A previous study showed that the prevalence of AF was significantly higher in Caucasian (8%) than in black (3.8%), Hispanic (3.6%), and Asian (3.9%) ethnic groups (17). Therefore, our study results supported that the prevalence of AF in Asian patients with AMI was relatively lower when compared with Caucasians although more data should be collected (16).

Although the presence of AF during AMI has been associated with a worse prognosis (4), OAC was underused, in only ~15% of the AMI patients with AF undergoing PCI with a stent in the current study. Previous US registry reported only 27% (n = 448) of the total population received triple therapy at discharge among the 1,648 patients with AF with non-ST-elevation myocardial infarction who underwent PCI (18). The Swedish registry also reported the only 30% (1,848/6,182) of total AMI patients with AF admitted from 1995 to 2002 were prescribed OAC (19). The tendency of underused OAC in the current and previous studies could be explained by the concern regarding bleeding complications when patients were treated with triple therapy. Previous nationwide cohort study with AF patients following AMI and PCI showed that triple therapy increased both early and delayed bleeding risk compared with DAPT (20). Therefore, the concern for major bleeding may have affected the decision of physicians to not use OAC. However, since the introduction of non-vitamin K oral anticoagulants (NOACs), recent studies consistently showed a significant reduction in major bleeding with NOAC-based treatment compared with the vitamin K antagonist-based therapies, resulting in a rapid increase in triple therapy with NOAC after PCI for AMI in AF patients

TABLE 4 | Detail information of CHA₂DS₂-VASc Score.

Characteristics	OAC (n = 71)	No OAC (n = 382)	p value
Index			
C CHF	40 (56.3)	148 (38.7)	<0.01
H Hypertension	49 (69.0)	217 (56.8)	0.055
A2 Age ≥ 75 years	25 (35.2)	136 (35.6)	0.95
D Diabetes mellitus	33 (46.5)	88 (23.0)	<0.01
S2 Prior stroke or TIA or thromboembolism	17 (23.9)	23 (6.0)	<0.01
V Vascular disease	71 (100)	382 (100)	–
A Age 65–74 years	32 (45.1)	113 (29.6)	0.01
Sc female gender	27 (38.0)	89 (23.3)	<0.01
CHA ₂ DS ₂ -VASc Score	4.7 ± 1.6	3.6 ± 1.7	<0.01
Score ≥ 2	69 (97.2)	337 (88.2)	0.02
Score ≥ 3	66 (93.0)	266 (69.6)	<0.01
Score ≥ 4	55 (77.5)	192 (50.3)	<0.01
Score ≥ 5	40 (56.3)	109 (28.5)	<0.01
Score ≥ 6	25 (35.2)	46 (12.0)	<0.01
Score ≥ 7	7 (9.9)	19 (5.0)	0.10

Data are presented as the mean ± SD or number (%). OAC, oral anticoagulant; CHF, congestive heart failure; TIA, transient ischemic attack.




FIGURE 3 | The trend of detailed distributions of the CHA2DS2-VASc scores.

TABLE 5 | Univariate and multivariate analyses regarding the determinants for OAC usage.

Variables	Univariate analysis		Multivariate analysis [†]	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age ≥ 75 years	0.98 (0.58–1.67)	0.95		
Body mass index, kg/m ²	1.05 (0.97–1.13)	0.24		
Female gender	2.02 (1.18–3.45)	0.01	2.11 (1.17–3.79)	0.01
Hypertension	1.69 (0.99–2.91)	0.06	1.02 (0.56–1.87)	0.95
Diabetes mellitus	2.90 (1.72–4.90)	<0.01	2.37 (1.35–4.17)	<0.01
Dyslipidemia	1.99 (0.89–4.44)	0.09	1.77 (0.73–4.29)	0.21
Prior CVA	4.91 (2.47–9.79)	<0.01	4.19 (2.00–8.75)	<0.01
CKD ≥ stage 4 (eGFR<30)	1.03 (0.34–3.09)	0.96		
NSTEMI	1.55 (0.93–2.57)	0.09	1.46 (0.84–2.53)	0.18
CHA ₂ DS ₂ -VASc Score ≥ 2	4.61 (1.09–19.44)	0.04	1.51 (0.32–7.21)	0.60
CHF	2.04 (1.22–3.41)	<0.01	1.89 (1.09–3.30)	0.02
Anemia (Hb < 11 g/dL)	0.98 (0.39–2.42)	0.96		
Thrombocytopenia (platelet count < 100 × 10 ⁹ /L)	0.77 (0.09–6.32)	0.80		
LM involvement	1.14 (0.38–3.46)	0.82		
Stent number	0.92 (0.52–1.65)	0.79		
Mean stent diameter	0.88 (0.49–1.57)	0.67		
Total stent length	0.99 (0.98–1.02)	0.84		

[†] Any variable with P < 0.1 on univariate analysis was included in the multivariate models.

OAC, oral anticoagulant; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; CHF, congestive heart failure; Hb, hemoglobin; LM, left main artery.

(21). As a result, the current guidelines recommend the preferable use of NOAC over vitamin K antagonists (21). In the era of NOAC, further study regarding recent trends of antithrombotic therapy in patients with AF and AMI is needed.

Cardiac catheterization with radial access has been reported to be more beneficial than femoral access with fewer occurrences of hemorrhagic events and short-term cardiac death (22). In the current study, only 27.6% (125/453) of total patients underwent PCI via transradial access. The proportion of transfemoral access

is somewhat high, which may have affected the operator to be reluctant to prescribe OAC.

There are concerns regarding the major bleeding due to the intensive combination antithrombotic therapy. Thus, current guidelines recommend that early cessation of aspirin and continuation of dual antithrombotic therapy with an OAC plus clopidogrel up to 6–12 months in patients with AF at increased risk of stroke (CHA₂DS₂-VASc score \geq 2) who have undergone PCI with stent implantation for ischemic heart disease (7, 8). Although this study was a study of patients from November 2011 to December 2015, the ESC guideline for STEMI published in 2012 also strongly recommended triple therapy with minimal duration to reduce bleeding risk in patients with obligatory indication for OAC after stent placement (Class 1, Level C) (23). However, unlike the recommendation of the guidelines, 14.8% (67/453) of AF patients who underwent PCI for AMI were treated with triple therapy at discharge, of which the majority of patients (58.2%) maintained triple therapy for 1 year. Therefore, further research and discussion on this area are needed.

A previous nationwide population-based study reported that the prior CVA history and congestive heart failure were significantly associated with a higher triple prescription rate in patients with AF undergoing PCI (9). In the current study, we also found that the prior CVA history and a history of CHF or the presence of moderate to severe LV systolic impairment were significant determinants for physicians to the use of OAC. Additionally, female gender and diabetes mellitus were significant factors affecting OAC usage. Among the components of the CHA₂DS₂-VASc score, our study results showed that older age and hypertension did not affect the use of OAC. This might be explained by the fact that previous studies, including the current study, were for patients with ischemic heart disease and AF, rather than overall AF patients, indicating different characteristics of OAC usage.

This study had several limitations. First, this study was a non-randomized, observational study, which has inherent selection and information biases. Second, the current study was conducted on patients registered in the registry, thus the results were difficult to apply with representation and in hypothesis generation. Third, details of the prescription of the OAC such as treatment duration of OAC and type of OAC (vitamin K antagonist or NOAC) were not considered. However, we identified the trend of change in antithrombotic therapy between the hospital discharge and 12 months after PCI. Fourth, currently available data did include only in-hospital bleeding events. Fifth, the comparison of 12-month clinical outcome was done by classifying the patients based on OAC usage at the time of hospital discharge without considering the treatment duration or type of OAC, or concomitant antiplatelet agents, so the results should be interpreted with caution. Nevertheless, this study expects physicians to be able to understand the trends in the use of OAC usage in patients with AMI and AF.

CONCLUSION

The nationwide prospective dedicated AMI registry demonstrated that the prevalence of AF was 5.4% in patients with AMI. Moreover, contrary to the guidelines, OAC was underused, in only ~15% of the AMI patients with AF undergoing PCI with a stent in real-world practice. The significant determinants for the use of OAC were female gender, diabetes mellitus, prior CVA history, and a history of CHF or the presence of moderate to severe LV dysfunction, although the older age and hypertension did not affect the use of OAC among the components of the CHA₂DS₂-VASc score.

DATA AVAILABILITY STATEMENT

The data supporting the conclusions of this article are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of each participating center. The approval number was CNUH-2011-172 at Chonnam National University Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

O-HL and YK study concept and design, acquisition, analysis, and interpretation of data, drafting for the manuscript, and critical revision of the manuscript for important intellectual content. YK, D-KC, J-SK, B-KK, DC, M-KH, MJ, and YJ acquired the data. D-KC, DC, M-KH, and YJ supervised the progress of the study. All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This work was supported by a faculty research grant from Yonsei University College of Medicine (6-2020-0161) and a research seed money grant of Internal Medicine in Yongin Severance Hospital.

ACKNOWLEDGMENTS

The authors would like to thank the clinical investigators of the Korea Acute Myocardial Infarction Registry.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcvm.2021.762090/full#supplementary-material>

REFERENCES

- Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *JAMA*. (2001) 285:2370–5. doi: 10.1001/jama.285.18.2370
- Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J*. (2013) 34:2746–51. doi: 10.1093/eurheartj/ehz280
- Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. *JAMA Intern Med*. (2014) 174:107–14. doi: 10.1001/jamainternmed.2013.11912
- Wong C-K, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. *Am Heart J*. (2000) 140:878–85. doi: 10.1067/mhj.2000.111108
- Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. *Lancet*. (2006) 367:1903–12. doi: 10.1016/S0140-6736(06)68845-4
- Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. *N Engl J Med*. (1998) 339:1665–71. doi: 10.1056/NEJM199812033392303
- January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. *J Am Coll Cardiol*. (2019) 74:104–32. doi: 10.1016/j.jacc.2019.01.011
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. (2021) 42:373–498. doi: 10.1093/eurheartj/ehaa945
- Park J, Choi E-K, Han K-D, Choi Y-j, Lee E, Choe W, et al. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: a nationwide Korean population-based study. *PLoS ONE*. (2019) 14:e0209593. doi: 10.1371/journal.pone.0209593
- Kim JH, Chae S-C, Oh DJ, Kim H-S, Kim YJ, Ahn Y, et al. Multicenter Cohort Study of acute myocardial infarction in Korea—Interim Analysis of the Korea acute myocardial infarction registry-national institutes of health registry. *Circ J*. (2016) 80:1427–36. doi: 10.1253/circj.CJ-16-0061
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. (2010) 137:263–72. doi: 10.1378/chest.09-1584
- Urban P, Mehran R, Collieran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. *Eur Heart J*. (2019) 40:2632–53. doi: 10.1093/eurheartj/ehz372
- Lee S-R, Choi E-K, Han K-D, Cha M-J, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. *Int J Cardiol*. (2017) 236:226–31. doi: 10.1016/j.ijcard.2017.02.039
- Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. *Am Heart Journal*. (2002) 143:519–27. doi: 10.1067/mhj.2002.120410
- Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS, Investigators O. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. *Eur Heart J*. (2005) 26:350–6. doi: 10.1093/eurheartj/ehi064
- Dai Y, Yang J, Gao Z, Xu H, Sun Y, Wu Y, et al. Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry. *BMC cardiovasc disord*. (2017) 17:1–8. doi: 10.1186/s12872-016-0442-9
- Shen AY-J, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults—a cross-sectional study. *J Natl Med Assoc*. (2010) 102:906–13. doi: 10.1016/S0027-9684(15)30709-4
- Fosbol EL, Wang TY, Li S, Piccini J, Lopes RD, Mills RM, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. *Am Heart J*. (2013) 166:864–70. doi: 10.1016/j.ahj.2013.08.005
- Stenstrand U, Lindbäck J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and knowledge about Swedish heart intensive care admissions s(RIKS-HIA). *Circulation*. (2005) 112:3225–31. doi: 10.1161/CIRCULATIONAHA.105.552984
- Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. *Circulation*. (2012) 126:1185–93. doi: 10.1161/CIRCULATIONAHA.112.114967
- Potpara TS, Mujovic N, Projetti M, Dagres N, Hindricks G, Collet JP, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trial. *Europace*. (2020) 22:33–46. doi: 10.1093/europace/euz259
- Cesaro A, Moscarella E, Gragnano F, Perrotta R, Diana V, Pariggiano I, et al. Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. *Expert Rev Cardiovasc Ther*. (2019) 17:435–47. doi: 10.1080/14779072.2019.1627873
- Steg PG, James SK, Atar D, Badano LP, Blömmström-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. (2012) 33:2569–619. doi: 10.1093/eurheartj/ehs215

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Lee, Kim, Cho, Kim, Kim, Choi, Hong, Jeong, Jang and the KAMIR-NIH Investigators. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.